For the parents of a child with a severe form of epilepsy, the most harrowing moments often happen in the silence between doctor’s appointments. In the clinical setting, a neurologist has the benefit of specialized equipment and a controlled environment. But in the living room, the bedroom, or the school bus, the reality is far more chaotic. Seizures are unpredictable; their patterns shift, and the nuances of how a patient responds to medication are often lost in the gap between a monthly visit and the daily struggle of caregiving.
This “data void” has long been a primary hurdle in treating complex neurological conditions. When physicians rely on caregiver journals or sporadic clinic observations, they are essentially trying to solve a puzzle with half the pieces missing. For those living with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS)—two of the most challenging forms of epilepsy—this lack of objective, continuous data can mean the difference between a treatment that works and one that fails to address the true burden of the disease.
Addressing this gap requires more than just better medicine; it requires a fundamental shift in how patient data is collected. For the past decade, the biopharmaceutical company UCB has partnered with Byteflies, a Belgian digital health firm, to move the diagnostic laboratory into the home. By leveraging multimodal wearable technology, the partnership is attempting to turn the “black box” of daily life into a stream of actionable medical intelligence.
The collaboration represents a broader trend in the pharmaceutical industry known as Digital Care Transformation (DCTx). Rather than focusing solely on the molecule, companies are increasingly investing in the ecosystem around the drug—using data to refine dosing, identify seizure triggers, and reduce the immense psychological and physical burden on caregivers.
From Exploration to Evidence: The Evolution of SeizeIT and TETRIS
The partnership between UCB and Byteflies did not begin as a polished product, but as a shared curiosity. In 2016, the two organizations launched SeizeIT, an early-stage initiative designed to test whether wearable devices could meaningfully complement traditional epilepsy care. At the time, the goal was exploratory: could a device worn by a patient provide a clearer picture of seizure activity than a handwritten log?
Over the last eight years, this exploration has matured into a rigorous scientific framework. The transition from a pilot project to a clinical tool is most evident in the TETRIS study. Unlike early prototypes, TETRIS is a real-world study specifically designed to evaluate how remote, multimodal monitoring can assist physicians in making more informed decisions for patients with DS and LGS.
The shift toward “real-world evidence” is critical in rare disease research. Because DS and LGS affect a relatively slight population, traditional clinical trials often struggle with limited sample sizes. By collecting continuous data from patients in their natural environments, UCB and Byteflies are creating a more robust dataset that reflects how these diseases behave in the wild, rather than how they appear in a sterile clinic.
Decoding the Brain: How Multimodal Wearables Work
At the center of this technological push is Byteflies’ wearable hardware. While many consumer wearables track heart rate or steps, the Byteflies system is designed for clinical-grade neurological monitoring. It employs a “multimodal” approach, meaning it collects several different types of biological data simultaneously to create a comprehensive map of a seizure event.
The system integrates three primary streams of data:
- Electroencephalography (EEG): Monitoring the electrical activity of the brain to identify the specific “signatures” of a seizure.
- Electrocardiogram (ECG): Tracking heart rate and rhythm, which often change predictably during and after a seizure.
- Actigraphy: Using accelerometers to track physical movement and sleep disturbances, which are common comorbidities in severe epilepsy.
By combining these three metrics, clinicians can perform more accurate “phenotyping”—the process of identifying the specific characteristics of a patient’s epilepsy. For example, a seizure might look one way on an EEG but be accompanied by a specific heart rate spike and a particular movement pattern. When these are viewed together, the diagnostic clarity is far higher than any single metric could provide.
This approach also mitigates the “white coat effect,” where a patient’s symptoms change due to the stress of being in a hospital. By monitoring patients at home, the data collected is more representative of their actual lived experience, leading to more reliable treatment adjustments.
The Human Cost of Clinical Gaps
The technical specifications of EEG and ECG are secondary to the impact on the family unit. For caregivers of children with LGS or Dravet syndrome, the burden of care is exhaustive. Traditional video EEG monitoring often requires hospital stays, which are disruptive and stressful for patients who may already struggle with sensory sensitivities or sleep disorders.
Remote monitoring shifts the burden from the human to the hardware. Instead of a parent spending hours meticulously documenting every twitch or lapse in consciousness, the wearable captures the data objectively. This not only provides the doctor with better information but grants the caregiver a degree of mental relief, knowing that the “invisible” symptoms are being recorded.
The following table outlines the shift in care delivery enabled by this partnership:
| Feature | Traditional Clinic Care | Remote Multimodal Monitoring |
|---|---|---|
| Data Frequency | Episodic (during appointments) | Continuous (real-world) |
| Patient Environment | Clinical/Controlled | Natural/Home setting |
| Data Sources | Patient logs & short-term EEG | Integrated EEG, ECG, and Actigraphy |
| Caregiver Burden | High (manual tracking/travel) | Reduced (automated data collection) |
Scaling Responsible Innovation
The long-term success of this partnership depends on more than just the hardware; it depends on the responsible handling of highly sensitive neurological data. As UCB and Byteflies move toward scaling these solutions, the focus has shifted toward “responsible innovation”—ensuring that the data is used to improve outcomes without compromising patient privacy or overwhelming physicians with “data noise.”
The goal is not to replace the neurologist, but to provide them with a filtered, high-fidelity summary of what happened between visits. This allows the physician to spend less time questioning the patient about the past month and more time adjusting the treatment plan based on objective evidence.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients and caregivers should consult with a healthcare professional for diagnosis and treatment of epilepsy or other neurological conditions.
The next phase of this collaboration will center on the continued analysis of the TETRIS study results and the potential integration of these monitoring tools into broader clinical practice. As the industry moves toward personalized medicine, the ability to track a patient’s unique neurological signature in real-time will likely become the standard of care for rare and complex epilepsies.
Do you think remote monitoring will eventually replace traditional clinic visits for chronic conditions? Share your thoughts in the comments or share this story with a colleague in the health-tech space.
